One example:
The table didn’t paste over right, but the id names are correct in the summary
| Peak | Rt (min) | Area% | ID |
| 1 | 15.323 | 2.84% | 17β-(4-Methylbenzenesulfonyloxy)androst-4-en-3-one |
| 2 | 15.457 | 3.22% | Acrylophenone, 2,2’,5’-trimethyl- |
| 3 | 20.638 | 76.97% | Testosterone cypionate (parent) |
| 4 | 20.709 | 16.97% | 4,6-Androstadien-17β-ol-3-one |
Peak 3 — Testosterone cypionate (76.97%)
- This is the main product but at only ~77% area — low purity. Potency will likely be lower than labeled unless an independent assay says otherwise.
Peak 4 — 4,6-Androstadien-17β-ol-3-one (16.97%)
- Large secondary peak (≈17%). This is an unsaturated steroid (an androstadienone-type compound) and is most consistent with structural isomerization or oxidative/dehydrogenation degradation of the parent steroid.
- Because it’s substantial in amount, it’s the main impurity of concern. It may alter biological effect and could increase side-effect/unknown-toxicity risk compared with pure testosterone cypionate.
Peak 1 — 17β-(4-Methylbenzenesulfonyloxy)androst-4-en-3-one (2.84%)
- This is a tosylate (p-toluenesulfonyl) ester/derivative attached to the steroid — strongly suggests a synthetic/by-product impurity from the manufacturing process (a protection/activation reagent left over or incomplete work-up).
- Even at ~3%, a tosylated steroid impurity is not something you want in an injectable product — potential reactivity/irritation.
Peak 2 — Acrylophenone, 2,2’,5’-trimethyl- (3.22%)
- This is an aromatic ketone; likely solvent/reagent contaminant, degradation of an organic reagent, or a column artifact. Not a normal steroid impurity. Could be from contaminated glassware, solvents, or reagents used in synthesis. Also not desirable.